Rick Finnegan returned to rEVO in 2014 as senior vice president of program management previously serving as vice president of corporate development for the company from 2007 to 2008 when it known as Genzyme Transgenics Corporation. Prior to rEVO, Mr. Finnegan was executive vice president for global strategic accounts and commercial development at inVentiv Health from 2010 to 2013 where he expanded inVentiv's commercial footprint into China and Europe. From 1984 through 2010, Mr. Finnegan's experience included roles at leading biopharma companies including twelve years in various commercialization assignments at Merck, two years at Genzyme as vice president of new products, three years as senior vice president of sales and marketing at Critical Therapeutics, and three years at Glenmark Pharmaceuticals where, based in Prague, he led their European specialty pharma business.
Mr. Finnegan holds a B.S. in business administration with a concentration in life sciences from the Whittemore School of Business and Economics at the University of New Hampshire and an M.S. in management from the Sloan School of Management at Massachusetts Institute of Technology.
Senior Vice President, Program Management